HUP0001380A2 - Isoquinoline derivatives as hiv protease inhibitors, and pharmaceutical compositions containing them - Google Patents

Isoquinoline derivatives as hiv protease inhibitors, and pharmaceutical compositions containing them

Info

Publication number
HUP0001380A2
HUP0001380A2 HU0001380A HUP0001380A HUP0001380A2 HU P0001380 A2 HUP0001380 A2 HU P0001380A2 HU 0001380 A HU0001380 A HU 0001380A HU P0001380 A HUP0001380 A HU P0001380A HU P0001380 A2 HUP0001380 A2 HU P0001380A2
Authority
HU
Hungary
Prior art keywords
ring
alkyl
substituted
groups
hydrogen atom
Prior art date
Application number
HU0001380A
Other languages
Hungarian (hu)
Inventor
Kim F. Albizati
Takuo Kobayashi
Siegfried Heinz Reich
Michael D. Varney
Kanyin E. Zhang
Original Assignee
Agouron Pharmaceuticals Inc.
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals Inc., Japan Tobacco Inc. filed Critical Agouron Pharmaceuticals Inc.
Publication of HUP0001380A2 publication Critical patent/HUP0001380A2/en
Publication of HUP0001380A3 publication Critical patent/HUP0001380A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A találmány (9) általánős képletű vegyületekre, a képletben R és R'jelentése egymástól függetlenül hidrőgénatőm, helyettesített vagyhelyettesítetlen alkil-ORl általánős képletű csőpőrt,ciklőalkilcsőpőrt, amely 1-6 szénatőmős alkilcsőpőrttal vagy 1-6szénatőmős hidrőxi-alkil-csőpőrttal helyettesített, heterőciklűsőscsőpőrt, amely 1-6 szénatőmős alkilcsőpőrttal vagy 1-6 szénatőmőshidrőxi-alkil-csőpőrttal helyettesített, alkil-NR2R3 vagy alkil-S (X)(Y) R4 általánős képletű csőpőrt, ezekben Rl jelentése hidrőgénatőm,helyettesített vagy helyettesítetlen alkilcsőpőrt vagy acilcsőpőrt; R2és R3 jelentése egymástól függetlenül hidrőgénatőm, helyettesítettvagy helyettesítetlen alkilcsőpőrt, ciklőalkilcsőpőrt, heterőciklűsőscsőpőrt és arilcsőpőrt, és acilcsőpőrt és szűlfőnilcsőpőrt; R4jelentése hidrőgénatőm, helyettesített vagy helyettesítetlenalkilcsőpőrt, ciklőalkilcsőpőrt, heterőciklűsős csőpőrt vagyarilcsőpőrt; és X és Y jelentése egymástól függetlenül =O csőpőrt vagysemmi; vagy gyógyászatilag elfőgadható előgyógyszerükre, sójűkra vagyszőlvátjűkra vőnatkőzik, amelyek HIV prőteáz gátló hatásúak, és HIV-fertőzés és AIDS kezelésére alkalmazhatók. ŕFor the compounds of the general formula (9) of the invention, R and R' in the formula are independently hydrogen atom, substituted or unsubstituted alkyl-ORl ring powder, cyclic alkyl ring powder, which is substituted with 1-6 carbon ring alkyl ring ring or 1-6 carbon ring hydroxyalkyl ring ring, heterocyclic ring ring ring, which is substituted by 1 to 6 carbon atom alkyl or 1 to 6 carbon hydroxyalkyl, alkyl-NR2R3 or alkyl-S (X)(Y) R4 general formula, in which Rl is a hydrogen atom, substituted or unsubstituted alkyl or acyl; R 2 and R 3 are independently hydrogen atom, substituted or unsubstituted alkyl groups, cyclic alkyl groups, heterocyclic groups and aryl groups, and acyl groups and phenyl groups; R4 represents a hydrogen atom, substituted or unsubstituted alkyl, cyclic alkyl, heterocyclic, or aryl; and X and Y, independently of each other, =O pipe dust or nothing; or they use their pre-medication, which can be boiled medicinally, salt or cranberry juice, which have an HIV protease inhibitory effect and can be used to treat HIV infection and AIDS. ŕ

HU0001380A 1997-03-13 1998-03-12 Isoquinoline derivatives as hiv protease inhibitors, and pharmaceutical compositions containing them HUP0001380A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81595197A 1997-03-13 1997-03-13
PCT/US1998/004735 WO1998040357A2 (en) 1997-03-13 1998-03-12 Hiv protease inhibitors

Publications (2)

Publication Number Publication Date
HUP0001380A2 true HUP0001380A2 (en) 2000-09-28
HUP0001380A3 HUP0001380A3 (en) 2001-12-28

Family

ID=25219265

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001380A HUP0001380A3 (en) 1997-03-13 1998-03-12 Isoquinoline derivatives as hiv protease inhibitors, and pharmaceutical compositions containing them

Country Status (35)

Country Link
EP (1) EP0970055A2 (en)
JP (1) JP2001516350A (en)
KR (1) KR100511089B1 (en)
CN (1) CN1179948C (en)
AP (1) AP1358A (en)
AR (1) AR012556A1 (en)
AU (1) AU743078B2 (en)
BG (1) BG63540B1 (en)
BR (1) BR9808867A (en)
CA (1) CA2284163A1 (en)
CO (1) CO4940496A1 (en)
CZ (1) CZ296647B6 (en)
EA (1) EA002378B1 (en)
EE (1) EE04114B1 (en)
GE (1) GEP20022764B (en)
HR (1) HRP980112A2 (en)
HU (1) HUP0001380A3 (en)
IL (2) IL131870A0 (en)
IS (1) IS5176A (en)
MX (1) MXPA99008395A (en)
MY (1) MY117535A (en)
NO (1) NO315555B1 (en)
NZ (1) NZ337706A (en)
OA (1) OA11196A (en)
PA (1) PA8448801A1 (en)
PE (1) PE58799A1 (en)
PL (1) PL192786B1 (en)
SA (1) SA98181116B1 (en)
SK (1) SK283636B6 (en)
SV (1) SV1998000038A (en)
TR (1) TR199902508T2 (en)
TW (1) TW200517112A (en)
UA (1) UA57772C2 (en)
WO (1) WO1998040357A2 (en)
ZA (1) ZA982047B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
TR199902508T2 (en) 2000-02-21
NZ337706A (en) 2001-04-27
EE9900416A (en) 2000-04-17
CZ296647B6 (en) 2006-05-17
IL131870A (en) 2006-04-10
IL131870A0 (en) 2001-03-19
ZA982047B (en) 1998-09-28
PE58799A1 (en) 1999-07-12
EA199900823A1 (en) 2000-04-24
CO4940496A1 (en) 2000-07-24
EE04114B1 (en) 2003-08-15
SV1998000038A (en) 1999-02-15
AU6457598A (en) 1998-09-29
CN1179948C (en) 2004-12-15
MY117535A (en) 2004-07-31
PL192786B1 (en) 2006-12-29
TW200517112A (en) 2005-06-01
NO994415L (en) 1999-11-10
OA11196A (en) 2003-05-21
PL335672A1 (en) 2000-05-08
UA57772C2 (en) 2003-07-15
BG63540B1 (en) 2002-04-30
EP0970055A2 (en) 2000-01-12
HRP980112A2 (en) 1998-12-31
BG103727A (en) 2000-04-28
AU743078B2 (en) 2002-01-17
AR012556A1 (en) 2000-11-08
PA8448801A1 (en) 2000-05-24
WO1998040357A2 (en) 1998-09-17
KR100511089B1 (en) 2005-08-31
KR20000076236A (en) 2000-12-26
CN1253548A (en) 2000-05-17
EA002378B1 (en) 2002-04-25
GEP20022764B (en) 2002-08-26
AP9901648A0 (en) 1999-09-30
MXPA99008395A (en) 2003-08-12
CA2284163A1 (en) 1998-09-17
JP2001516350A (en) 2001-09-25
HUP0001380A3 (en) 2001-12-28
NO994415D0 (en) 1999-09-10
SA98181116B1 (en) 2006-10-04
WO1998040357A3 (en) 1998-11-26
AP1358A (en) 2004-12-03
CZ319199A3 (en) 2000-06-14
NO315555B1 (en) 2003-09-22
SK283636B6 (en) 2003-11-04
SK122299A3 (en) 2000-05-16
BR9808867A (en) 2000-07-11
IS5176A (en) 1999-09-10

Similar Documents

Publication Publication Date Title
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
HUP0300565A2 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0402225A2 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
HUP0401253A2 (en) Dolastatin 10 derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0402313A2 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors, pharmaceutical compositions containing them and use thereof
HUP9700811A2 (en) Ring fused tetrahydropyridine-n-hydroxycarboxamide derivatives, pharmaceutical compositions containing them and process for preparing them
HUP0001507A2 (en) Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
TNSN05160A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
HUP9802694A1 (en) Benzamide derivatives, process for producing them and pharmaceutical compositions containing them
HRP20041137B1 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
HUP0204283A2 (en) Piperidine quinolyl propyl derivatives, preparation method and pharmaceutical compositions containing same
PT1140916E (en) CYCLE HETEROARIL ACETIS
HUP0203548A2 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401729A2 (en) Alkyne-aryl-naphthyridin-4(1h)-one derivaties as phosphodiesterase-4 inhibitors and pharmaceutical compositions containing them
HUP0002353A2 (en) 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phoshodiesterase iv inhibitory activity and pharmaceutical compositions containing them
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
HUP0301341A2 (en) Piperidine derivatives of ccr-3 inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0002272A2 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
HUP0201722A2 (en) Pharmaceutical compositions for treating alcoholism and alcohol dependence
HUP0101963A2 (en) Succinamide inhibitors of interleukin-1betha converting enzyme
HUP0301587A2 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect, pharmaceutical compositions containing them and processes for their preparations
EA200300044A1 (en) NEW SUBSTITUTED PHTHALIDES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
CA2085796A1 (en) 3(2h)-pyridazinone derivatives and process for the preparation thereof
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
HUP0303204A2 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees